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2352-3042/Copyright ª 2014, ChongqAbstract Gene therapy has been considered as the most ideal medical intervention for genetic
diseases because it is intended to target the cause of diseases instead of disease symptoms. Avail-
ability of techniques for identification of genetic mutations and for in vitromanipulation of genes
makes it practical and attractive. After the initial hype in 1990s and later disappointments in clin-
ical trials for more than a decade, light has finally come into the tunnel in recent years, especially
in the field of eye gene therapy where it has taken big strides. Clinical trials in gene therapy for
retinal degenerative diseases such as Leber’s congenital amaurosis (LCA) and choroideremia
demonstrated clear therapeutic efficacies without apparent side effects. Although these success-
ful examplesare still rareand sporadic in thefield, theyprovide theproof of concept forharnessing
the power of gene therapy to treat genetic diseases and tomodernize ourmedication. In addition,
those success stories illuminate the path for the development of gene therapy treating other ge-
netic diseases. Because of the differences in target organs and cells, distinct barriers to gene
delivery exist in gene therapy for each genetic disease. It is not feasible for authors to review
thecurrent development in theentirefield. Thus, in this article,wewill focus onwhatwecan learn
from the current success in gene therapy for retinal degenerative diseases to speed up the gene
therapy development for lung diseases, such as cystic fibrosis.
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Prospects of gene therapy for inherited pulmonary diseases 41IntroductionIn 2008, three research teams independently reported the
success in clinical trails of gene therapy treating a rare form
of retinal degenerative diseases called Leber’s congenital
amaurosis (LCA).1e3 LCA represents a group of inherited
blindness with childhood onset.4 The clinical success has
been achieved in treating LCA2, one form of the disease,
which is caused by mutations in the retinal pigment
epithelium-specific 65-kDa protein gene (REP65). REP65
encodes a protein providing the isomerohydrolase activity
for the retinal pigment epithelium to produce 11-cis-retinal
from all-trans-retinyl esters during the visual cycle for
regenerating the visual pigment after exposure to light.
Without this gene function, 11-cis-retinal, the natural ligand
and chromophore of the opsins of photoreceptor cells,
cannot be regenerated, thus rendering the opsins incapable
of capturing light or transducing it into electrical responses
for initiating vision. Although this defect in light trans-
duction has an immediate impact on visual function, retinal
cell degeneration is delayed in patients, thus making target
cells available for gene therapy. The three teams tested the
same therapeutic approach in patients by subretinal injec-
tion of recombinant adeno-associated virus vector 2 (AAV2)
expressing the RPE65 complementary DNA (cDNA). Patients
with treatment showed improvements in visual function
without serious adverse events. In 2012, three patients
received the same treatment in their other eye and all three
demonstrated improvements in visual and retinal function in
their second eyes after the treatment, which was adminis-
tered one-and-a-half to three-and-a-half years after their
first eyes were treated.5 Readministration of the same gene
therapy vector caused no harmful immune reactions in pa-
tients. In 2014, a gene therapy trial for another retinal
degenerative disease, choroideremia, was shown to be
successful.6 Choroideremia is an X-linked recessive disease
that is caused by mutations in the CHM gene, which encodes
the Rab escort protein 1 (REP1). The same gene therapy
vector, AAV2, was used in this study. In addition to the eye
gene therapy success, progress has been made in other
fields as well. For example, as a milestone for using gene
therapy as medicine, European Union approved Glybera as
the first gene therapy drug for a form of lipoprotein lipase
deficiency.7e9 In this case, AAV1 was used to deliver a
naturally occurring functional variant of the LPL gene
associated with lower rates of cardiovascular disease and
increased efficiency in fat metabolism. These clinical suc-
cesses provide the proof of concept that the power of gene
therapy can be harnessed to benefit human beings.
However, gene therapy developments for other dis-
eases, such as cystic fibrosis (CF) lung disease, are not as
successful for eye diseases.10e13 CF is the most common
monogenic fatal disorder in the Caucasian population and it
is caused by recessive mutations in the gene encoding the
cystic fibrosis transmembrane conductance regulator
(CFTR).14e16 Although the disease affects multiple organs,
including the lung, pancreas, intestine, gall bladder and
reproductive organs,13,17 lung failure due to chronic infec-
tion and inflammation is currently responsible for most
morbidity and mortality. Therefore, CF gene therapy
studies to date have been aimed at treating the pulmonarymanifestations. When the cystic fibrosis gene was identified
in 1989, it appeared that this disease can be used as an
ideal model for the development of gene therapy for lung
diseases since airway epithelial cells where the CFTR gene
is expressed are readily accessible to gene therapy vectors.
Yet, all the CF clinical trials conducted so far did not show
any evidence of significant therapeutic benefits brought to
CF patients.18e35 Basic research in lung gene therapy de-
velopments later identified major barriers to vector de-
livery and sustained therapeutic gene expression.10,13,36
Thus, it is useful to look into what is fundamental to the
successful gene therapy development for eye diseases to
make lung gene therapy fruitful.
In this review article, we will first visit the early de-
velopments in CF lung therapy and look into the major
challenges encountered in the lung gene therapy field. We
will then review the key factors that are critical to the eye
gene therapy progress to explain the possible rationale for
the clinical success. We will finally discuss strategies that
can be translated from the eye gene therapy field to speed
up the lung gene therapy development.Early stages of lung gene therapy
developments
Because CF is a monogenic disease and the target cells in
lung airway are easily accessible to gene therapy vectors,
when the gene was identified, an illusion was created sug-
gesting that lung gene therapy for CF would be available in a
few years. The initial excitements inspired many scientists
racing in conducting clinical trials. Both viral and non-viral
gene therapy vectors were tested. One of the early clinical
studies was conducted by Zabner et al in 1993 to examine
the safety profile of an adenoviral (Ad) vector with nasal
applications.18 Adenoviruses contain a linear double-
stranded DNA and have been widely used as tools for gene
delivery because of their ability to infect both dividing and
non-dividing cells with a high efficiency, especially epithe-
lial cells. The early generations of Ad vectors were devel-
oped by deleting the E1 region within the viral genome to
prevent viral proliferation in transduced cells and/or other
regions such as E3 or E4 to increase the DNA carrying ca-
pacity. There are more than 50 serotypes of adenoviruses
identified so far.37 In this study, a serotype 2 adenoviral
vector expressing the human CFTR cDNA was administered
to a defined area of nasal epithelium in three patients.
Although this initial study showed some functional correc-
tion in nasal epithelial cells with no vector-related adverse
effects, more extensive studies later demonstrated with
similar methods that there was no significant functional
correction in nasal epithelia.19,21 The Ad vectors have also
been tested in the lung24e26 and none of the studies
demonstrated functional correction or efficacy in patients.
In addition to the early generations of Ad vectors, re-
combinant adeno-associated virus (AAV) vectors have also
been tested in CF patients.28,38,39 AAV is a replication-
defective parvovirus that depends on a helper virus,
either adenovirus or herpes virus, for its propagation during
lytic infection.40 It has a small single-stranded DNA genome
(about 4.7 kb). The advantage of AAV as a gene therapy
42 E. Xia et al.vector is that it does not elicit strong immune responses.
Because of its small DNA carrying capacity, it could not be
used to deliver large genes or genes with long DNA regula-
tory elements. Although there were no major adverse ef-
fects even when repeated administration was performed,38
these studies did not show significant benefits for patients
treated with vector delivery.
Non-viral vectors have also been tested clinically in CF
gene therapy since these vectors are considered to be safer
than viral vectors.10 Cationic liposomes, which are
composed of a cationic lipid and a neutral lipid, are
commonly used for gene delivery. There are many types of
cationic lipids available41 which are often mixed with one
or two commonly used neutral lipids, dio-
leoylphosphatidylethanolamine (DOPE) or cholesterol.10
Many clinical trials have been conducted with cationic li-
posomes to assess their potential for CF Therapy. The first
liposome CF trial was carried out in CF patients through
nasal administration29 and later, several other trials with
various liposome formulations were conducted.30e33 Similar
delivery methods were tested in the lung of CF patients and
the results were not encouraging.34,35Challenges that slowed the progress in the lung
gene therapy
Looking back at the aforementioned clinical studies, it is
now understandable; the reason for the lack of clinical
progress in the lung gene therapy for CF was that major
challenges to lung gene delivery were not fully appreciated
at the time. These challenges include 1) lacking efficient
vectors for airway gene expression, 2) host immune re-
sponses to vectors, 3) lacking efficient and safe methods for
vector delivery and 4) difficulty in maintaining long-term
therapeutic gene expression in airways where epithelial
cells turn over. The following sections will be devoted to
explain these challenges as well as progresses being made
towards overcoming these challenges.Efficient vectors for airway gene expression
It is apparent that all gene therapy vectors used in early
clinical studies of lung gene therapy were not adequate for
achieving the efficiency needed for functional correction in
patients. The first generation Ad vectors used in the clinical
studies could not confer sustained transgene expression
in vivo. The issue of lacking sustained transgene expression
from adenoviral vectors is often misunderstood because it
was interpreted as the lack of vector stability in vivo. In
fact, Ad vectors are stable in vivo; the reason that they
cannot confer sustained transgene expression is because
they elicit host immune responses (which will be addressed
later), which eliminate the transduced cells in vivo.
Although most Ad vectors have the E1 region deleted from
their genomes to prevent viral gene expression and prolif-
eration, leaky expression of viral genes does occur in
transduced cells,42,43 thus providing antigen for the host
immune system to attack the transduced cells. Therefore,
early generations of Ad vectors are not suitable for gene
replacement therapy.To reduce the host immune responses, helper-
dependent adenoviral (HD-Ad) vectors have been devel-
oped.36,44 In these vectors, all the viral coding sequences
have been deleted, thus eliminating the leaky viral gene
expression and rendering a large DNA carrying capacity to
the vectors. These vectors have also been called high ca-
pacity or gutless vectors45 and have been shown to confer
long term transgene expression when delivered to mouse
livers.46 Compared to the first generation Ad vectors, HD-Ad
vectors elicited reduced levels of inflammation and
conferred longer term of transgene expression when
delivered to mouse lungs.47 Our group has demonstrated
that the human CFTR gene can be efficiently delivered to
mouse lungs using the HD-Ad vector and that the CFTR
knockout mice treated with the CFTR expressing vector are
protected from acute lung infection with bacteria.48 We
have also showed that HD-Ad vectors can be used to deliver
genes to the lungs of rabbits49 and pigs.50 We have showed
that the human CFTR gene can be efficiently delivered to
pig lungs.50 However, up to date, HD-Ad vectors have not
been tested in human lungs.
The reasons for the AAV vector failing to meet the effi-
ciency required for CF lung gene therapy are different from
that of Ad vectors. One of the major limitations is the small
DNA carrying capacity of AAV vectors; once the CFTR cDNA
is packed into the vector, there is no room for carrying DNA
regulatory elements, such as cell-specific promoter or
enhancer, for CFTR gene expression.51,52 It was reported in
2008 that AAV vectors could deliver as much as 8.9 kb DNA
although with a reduced efficiency,53 but later it was found
that a single AAV particle could not deliver the large re-
porter genes and the cell transduction in this case may be
accomplished by two viral particles containing the 50 and 30
parts of the reporter genes.54 In addition, the AAV2 vector
is not very efficient for lung gene delivery.55
One strategy to expand the DNA carrying capacity is to
rely on trans-splicing of mRNAs in target cells. A large gene
can be packaged into two AAV vectors to generate two RNA
transcripts which are spliced into one functional mRNA.56,57
Since this strategy required two AAV vectors to carry each
part of a gene to transduce the same cell and it is not ex-
pected that all RNA transcripts are trans-spliced, the
transgene expression efficiency will likely be reduced.
Although the DNA carrying capacity of AAV vectors is not
easy to change, different serotype AAV vectors with better
transduction efficiency for lung airway cells can be
selected. For example, AAV5, AAV6, AAV9 and AAV6.2 are
better vectors for lung gene delivery55 than AAV2 that has
already been used in clinical trials. In addition, vector
tropism can be engineered for lung applications.58,59
The lack of success in using nonviral vectors for clinical
studies of CF lung gene therapy is understandable because,
unlike the viral vectors, there is no specific mechanism for
nonviral vectors to send the DNA payload into the nuclei of
target cells and perpetuate the existence of the thera-
peutic gene in the nuclei. For gene delivery with liposomal
vectors, the majority of the delivered DNA is degraded by
lysosomes before entering nuclei; nuclear entry is another
major barrier.60 Although non-viral vectors might be useful
for some other gene delivery applications, in our opinion, it
is difficult to use them for lung gene replacement therapy
due to the lack of efficiency in gene delivery. Although
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can tolerate weekly or even monthly gene delivery.Host immune responses
Host immune responses to gene therapy vectors are one of
the most important challenges that were previously
underestimated in early lung gene therapy development.
The lung is a very sensitive immunologic organ61 capable of
producing both strong innate and adaptive immune re-
sponses to pathogens and gene therapy vectors. Although
the adaptive immune response to viral vectors was recog-
nized early on and investigated extensively,62e65 the innate
immune response was not fully appreciated. This was
evident from the first and the only incidence of gene
therapy related death in 1999 when a patient who received
a high dose of an Ad vector via the hepatic artery suc-
cumbed to acute toxicity. Post-mortem confirmed that the
patient suffered from systemic inflammation, biochemi-
cally detectable disseminated intravascular coagulation,
and multiple organ failure within 98 h.66 Clearly this was
the result of patient’s innate immune system reacting to
the high dose of the Ad vector.
For airway gene delivery, the first innate immune
response is mediated by lung macrophages that quickly
engulf vector particles, reducing gene delivery to target
cells. The macrophages not only take up gene therapy
vectors and destroy them, but also initiate the production
of proinflammatory cytokines by interacting with lung
epithelial cells.67 Macrophages as well as epithelial cells
express Toll-like receptors (TLRs) and RIG-I-like (retinoid-
inducible gene-1-like) receptors, which recognize nucleic
acid and proteins derived from viral pathogens including
viral DNA, single-stranded RNA and double-stranded RNA.68
Inflammatory cytokines, such as TNF-a, IL-6, MIP-2 and MIP-
1a, are dramatically induced in macrophages upon Ad
vector delivery to mouse airways within 6 h.45,69 These
cytokines activate airway immune cells and structural cells
to produce more proinflammatory cytokines which could
lead to airway damage, if the host cannot shut down the
cascade. One of the important pathways involved in the
induction of inflammatory cytokines is the NF-kB signaling
pathway.70 A variety of inflammatory cytokines, such as IL-6
and IL-8, can be induced by the activation of NF-kB. In
humans, a high level of IL-8, a potent neutrophil chemo-
attractant, can cause neutrophil infiltration that leads to
tissue damage.71,72 Even by using non-viral vectors, bacte-
rial DNA can be recognized by Toll-like receptor 9 which
activates the NF-kB pathway.36,45 It has been recently re-
ported that cytosolic DNA is a danger signal that induces
interferons through the production of cyclic guanosine
monophosphateeadenosine monophosphate (cyclic
GMPeAMP, or cGAMP).73 Other immune cells, such as neu-
trophils and natural killer cells, are also recruited in
response to viral vector delivery, which can produce in-
flammatory mediators as well and cause tissue damage.
The innate immune response not only leads to acute
toxicity, but also enhances the adaptive immune response
(will be explained later).
One major strategy to avoid the host immune responses
is to avoid using unnecessary high vector dose. Since allgene therapy vectors elicit innate immune responses, the
lower the dose the weaker immune responses triggered in
the host. In addition, anti-inflammatory drugs may be used
transiently to reduce the innate immune responses around
the first few days following vector delivery. Finally, nonin-
vasive vector delivery methods should be used to reduce
host stress to dampen the host innate immune responses.
These points will be further discussed later.
The adaptive immunity relies on T- and B-lymphocytes to
produce cellular and humoral responses to infectious
agents. In mammals, the adaptive system is developed
postnatally. During the development, an extremely diverse
repertoire of receptors is generated randomly and each
receptor recognizing a unique antigen, is expressed on the
surface of one T lymphocyte only. T cells bearing useful
receptors are subsequently selected from billions of lym-
phocytes for clonal expansion by interacting with antigens.
Professional-antigen-presenting cells, normally dendritic
cells or macrophages present the antigens bound to the
MHC II molecules to helper T cells to activate them. Acti-
vation of helper T cells by antigen presenting cells also
requires a co-stimulatory signal, e.g., CD80 or CD86, on the
surface of the antigen-presenting cell to bind to CD28 on
the surface of the T cell.74 The expression of co-stimulatory
molecules is regulated by innate immunity,75 and there-
fore, the adaptive immunity is regulated by the innate
immunity. Helper T cells control other cells in the adaptive
immune system, such as activation of cytotoxic T cells to
destroy infected cells and B cells to produce antibodies.
After elimination of pathogens, some antigen-specific
clones of T and B cells remain as “memory” lymphocytes
so that the adaptive immune system remembers the anti-
gens and destroy them more quickly upon subsequent
exposure.
Early work from several groups62e64 demonstrated
clearly that both cellular and humoral responses are
involved in adenoviral vector-mediated gene transfer in
mice. Repeated delivery of viral vectors, or primary de-
livery to individuals with pre-existing immunity, or viral
vectors expressing foreign antigens, can cause strong
adaptive immune responses. Various strategies can be used
to overcome the host adaptive immune responses. First of
all, as described above, blocking the innate immune
response can reduce the adaptive immune response. Sec-
ondly, blocking co-stimulatory pathways can be used to
modulate the host adaptive immune responses. Several
groups showed that an antibody against CD40 ligand76,77 or
expressing CTLA4Ig, a fusion protein of cytotoxic T
lymphocyte-associated protein 4 (CTLA4) and the Fc
portion of immunoglobulin G (IgG), by the HD-Ad vector,
improved transgene expression in rodents.78,79
In addition, “serotype switching”80 can be used for
repeated delivery of recombinant viruses. Gene therapy is
initiated with one virus serotype, then switched to a second
serotype for a subsequent administration, thereby avoiding
attack by neutralizing antibodies specific to the first sero-
type.81,82 However, the level and duration of transgene
expression following serotype switching may be limited by
cross-reactive cytotoxic T lymphocytes that can also target
cells infected by the second serotype virus.82,83 Thus, viral
vectors expressing foreign antigens, such as the first gen-
eration Ad vectors, cannot be used. Finally, since all viral
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any viral coding proteins, in such case transient immune
modulation may be sufficient for blocking the adaptive
immune response. It was shown that cyclophosphamide
alone or in combination with cyclosporine A extended
transgene expression mediated by the first generation Ad
vector.62 Our group has demonstrated that transient
administration of cyclophosphamide allowed readministra-
tion of HD-Ad vectors with efficient expression of
transgenes.84Efficient and safe delivery to airway
How to deliver genes safely and effectively into the airway
cells is an area that is not extensively studied. In addition to
the immune barriers discussed above, there are physical
barriers to vector delivery. At the time when the early CF
gene therapy clinical studies were conducted, there was
not enough information regarding physical barriers to gene
delivery, such as the mucosal layer, airway innate immune
cells and physical protection by airway epithelial tight
junctions. The mucosal layer is the first line of airway de-
fense and it has been shown to inhibit viral trans-
duction.85e87 For an inflamed lung, such as in CF, excessive
secretion of mucus may be even more problematic for gene
delivery. In addition, as mentioned above, the airway im-
mune cells, mainly macrophages, can take and destroy a
large portion of gene therapy vectors delivered,69,88 thus
preventing them by reaching the target cells. More impor-
tantly, viral vectors used in CF lung gene therapy depend on
their receptors to gain entry into their target cells which
are airway epithelial cells. However, cellular receptors for
viral vectors, such as the coxsackie-adenoviral receptor
(CAR), are located not on the lumenal side, but on the
basolateral side of the airway that is not directly accessible
to vectors. Since airway epithelial cells are connected by
tight junction proteins, vectors delivered cannot reach the
basolateral side of the airway.
There are strategies that can be considered to overcome
these barriers. For reducing the inhibition from the mucus
layer, mucolytic reagents, such as nacystelyn, may be
used.17,89 In addition, various polycations, such as DEAE-
dextran, polylysines, polybrene, protamine, and branched
plyethylenimine have been shown to greatly enhance viral
vector delivery to mouse lungs.83 To reduce the loss of gene
therapy vector, lung macrophages can be depleted by
gadolinium chloride90 or liposome/dichloromethylene-
bisphosphonate.88,91 However, these approaches may be
too toxic to humans even though mice tolerate them well.
On the other hand, anti-inflammatory reagents such as
rooperol,92 methyl palmitate93 and mangiferin,94 that
inhibit the phagocytic activity of macrophages, may be
administered by aerosolization to the airway during vector
delivery. In addition, dexamethasone has been shown to
reduce the phagocytic activity of pulmonary macrophages
although it is not effective on peritoneal macrophages.95
Although the accessibility of receptors may not be an
issue with nonviral vectors, such as liposomes, it is impor-
tant for gene delivery with viral vectors. Studies with ani-
mals show that reagents, such as Ca2þ chelator, EGTA, can
be used to break the tight-junctions transiently forenhancing viral vector delivery to the lung.96 It has also
been shown that L-a-lysophosphatidylcholine (LPC) can
enhance viral vector delivery dramatically to the lung of
mice97 and rabbits49 although it is not clear whether LPC
breaks tight-junctions.
Since gene delivery to lung normally causes some levels
of innate immune responses, it is likely that less stress put
on the host with less invasive delivery method will elicit
weaker innate immune reactions and produce better results
of therapeutic gene expression. The delivery method itself
may also affect the outcome. For example, an optimized
aerosol delivery approach may give a much better vector
distribution in the lung than instillation.Sustained therapeutic gene expression in the lung
airway
Sustained therapeutic gene expression is important for lung
gene therapy because it is unlikely that gene therapy vec-
tors, no matter viral or nonviral, cannot be frequently
administered to the lung due to the host innate and adap-
tive immune responses to viral vectors and bacterial DNA in
nonviral vectors. The challenge has not been paid enough
attention because most of the lung gene therapy studies
have been focusing on achieving efficient therapeutic gene
expression. The sustained therapeutic gene is more difficult
to achieve in the lung than other organs, such as the eye
because the lung is an immunologically sensitive organ and
the airway cells turn over. For the loss of therapeutic gene
expression due to the host immune responses, strategies to
overcome this problem have to be considered from all as-
pects of the gene therapy design, such as vector choice,
vector dose and delivery methods. These issues are covered
in the section of immune barriers and will not be repeated
here.
Airway epithelial cells turn over naturally. In mice the
average half-life of the ciliated epithelial cells is about 6
months in the trachea and 17 months in the lung.98 In
humans, the lung epithelial cells may have similar life
spans, which may be reduced in diseased conditions. Two
strategies may be used to cope with the problem. The first
strategy is to allow vector re-administration with a long
interval, for example once a year, if the adaptive immune
responses to vectors can be avoided. This strategy cannot
be used if the vector expressed foreign antigens, such as
the leaky expression of viral genes seen in the early gen-
eration Ad vectors. However, it is expected that all future
gene therapy vectors do not express vector encoded viral
genes, thus transient immune suppression may be used to
control the adaptive immune problem. In fact, it has been
demonstrated in mice that HD-Ad vectors can be re-
administered through transient immunosuppression.84 The
second strategy is to deliver a vector that allows a thera-
peutic gene to be integrated safely in the airway progenitor
cells. One major concern for integration of therapeutic
genes to correct genetic diseases is the risk of random
insertion that could cause major side effects including
cancer development.99,100 Now this problem can be solved
through engineering site-specific endonucleases to select a
safe site for the integration.101e103 Three types of engi-
neered endonucleases have been studied for their potential
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finger nucleases (ZFNs) are the first type in this group,
engineered by combining the nonspecific nuclease domain
of the Fok I restriction endonuclease with a zinc finger DNA-
binding domain.104,105 ZFNs have now been used success-
fully for genome editing and site specific gene inser-
tion102,106 although engineering ZFNs for a new
chromosome site is still time-consuming. Recently, a new
class of engineered nucleases called transcription
activator-like effector nucleases (TALENs), has
emerged.107e110 Like ZFNs, TALENs use the same Fok I
nuclease domains for DNA cleavage. Unlike ZFNs, TALENs
can be easily engineered for any new integration site. More
recently, a third type of endonucleases was designed based
on the CRISPR/Cas9 (CRISPR-associated) system which is
involved in genome defense mechanisms in bacteria for
destroying foreign DNA.111e113 This CRISPR/Cas9 system is
engineered to contain a single protein, Cas9 and a small
RNA.114,115 Since a relatively short target sequence (only 13
out of 20 is required) is used for determination of the
cleavage site,116 its off-target effects117e119 have to be
extensively characterized before it is used for gene ther-
apy. Since HD-Ad vectors are highly efficient in gene de-
livery to airway cells with a large DNA carrying capacity, a
single vector can carry both the engineered site-specific
nuclease genes and a therapeutic gene for clinical
applications.Reasons for the recent clinical success in eye
gene therapy
There are several important factors that made the recent
success in eye gene therapy possible. First of all, the right
gene therapy vector was selected for the disease targeted.
For targeting LCA2, AAV2 vector is the right choice because
the therapeutic gene RPE65 is small enough for this type of
vectors which are efficient in transducing retinal pigment
epithelial cells.120 The cDNA of RPE65 is about 3.1 kb121
which allows AAV type vectors to have 1.6 kb room for
DNA elements to control the therapeutic gene expression.
For the LCA2 clinical studies, two types of DNA control el-
ements are used. The trial study by Bainbridge et al used
the human RPE65 gene promoter (1.4 kb) and the bovine
growth hormone polyadenylation signal to control the
RPE65 expression,2 whiles in studies1,3 by Maguire et al and
Cideciyan et al, the expression of RPE65 is under the con-
trol of the chicken b-actin promoter together with the
cytomegalovirus immediate early enhancer, the rabbit b-
globin intro/exon junction and the SV40 polyadenylation
signal. In addition to the carrying capacity good enough to
meet the delivery of therapeutic gene, AAV2 is efficient in
transducing retinal pigment epithelial (RPE) cells.120
Secondly, immune barrier to AAV vector delivery is less
of a problem for subretinal gene delivery because the
anterior chamber of the eye is an immune-privileged site122
and AAV elicits weaker immune responses compared to
other types of viral vectors.123 Immune privilege of the eye
is established through five mechanisms, blood: ocular bar-
riers, absence of lymphatic drainage pathways, soluble
immunomodulatory factors in aqueous humor, immuno-
modulatory ligands on the surface of ocular parenchymalcells and indigenous, tolerance-promoting antigen-pre-
senting cells.122 Since immune protection against patho-
gens can injure vital tissues in an innocent bystander
manner, immune privilege is regarded as an evolutionary
adaptation to enable local protection by immune effectors
without disrupting the function of the vital tissues, such as
light transduction by retinal cells.
Furthermore, RPE cells are ideal target cells for gene
therapy. Essentially, all AAV vectors are efficient in trans-
ducing RPE cells although it is not totally clear whether this
is due to the phagocytic activity of the RPE or the avail-
ability of the viral receptors on these cells.120 The struc-
tural position of the RPE cells allowing them to have more
surface area for interacting with the vectors delivered to
the subretinal space may be an advantage over other cells,
such as photoreceptor cells. In addition to AAV, HD-Ad
vectors can also transduce RPE in mice with a high effi-
ciency.124 For gene therapy, it is important to have the
target cells available when the vector is delivered.
Although LCA2 is an early onset disease, retinal cells are
well preserved in young patients,125 thus making functional
rescue possible. An additional advantage for RPE cells being
targets is that there is no cell turnover in the RPE layer so
that the therapeutic gene expression can be sustained.
Finally, right animal models have been tested in pre-
clinical studies of LCA2 gene therapy.125 For gene therapy
targeting a particular disease, it is important to test the
therapeutic approach in large animal models in addition to
rodent models because there are major differences in
organ anatomy, composition of cell types and gene function
as well as tolerance to foreign substances. For example,
mouse lungs do not have submucosal glands as in humans
and have different epithelial compositions, such as with
more Clara cells and less goblet cells in the large air-
ways.126e130 When the mouse CFTR gene is knocked out,
there are no major lung disorders as in CF patients or other
animal models for CF.131,132 Mice can tolerate endotoxin,
LPS, at least 1000 time better than humans133,134 suggesting
that there may be differences in tolerance to other sub-
stances such as gene therapy vectors. Before clinical tests
in LCA2 patients, several research teams135e139 demon-
strated proof of concept for gene replacement therapy in a
canine model that is homozygous for a null mutation in
RPE65 in addition to tests done in mice.140 These animal
studies provided evidence for long term functional correc-
tion without apparent adverse effects to support clinical
applications.What can be learned from eye field to improve
lung gene therapy
The trajectory of the eye gene therapy research sheds new
light into several areas of the lung gene therapy develop-
ment. First of all, we need to select the right vector for
each particular lung disease. If a disease requires long term
therapeutic gene expression in airway epithelial cells, such
as in CF, a highly efficient vector with a large DNA carrying
capacity and capability to confer long term transgene
expression, should be considered to avoid frequent read-
ministration. Frequent readministration of gene therapy
vectors to lung is unlikely to be tolerated, especially for CF
Figure 1 Schematic diagram showing viral entry and transport. This figure was reproduced from the review article by Bran-
denburg and Zhuang141 with permission from Nature Publishing Group. The diagram summarizes viral entry and travel in mammalian
cells. Viruses attach to the plasma membrane, surf on the cell surface or along the filopodia (1e3), and bind to specific receptors
before entering the cell. Viruses can directly fuse with the plasma membrane (2). They also hijack endocytic pathways, including
clathrin-dependent (1), caveolin-dependent (3) or clathrin- and caveolin-independent (4) pathways for internalization. After
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Figure 2 Expression of human CFTR protein in pig airway epithelial cells. An HD-Ad vector containing the human CFTR gene
driven by the human cytokeratin 18 gene promoter was aerosolized to pig lungs. One week after delivery, lung tissues were taken
and immunostaining was performed on tissue sections to visualize the human CFTR protein. Left panel shows the human CFTR
protein located at the apical membrane of pig airway epithelial cells as the green immunofluorescence. The red immunofluo-
rescence was from staining with an antibody against Zou-1(an epithelial tight junction molecule) marking the cells as airway
epithelial cells. Right panel, a section of pig lung without vector transduction was immunostained in the same way as a negative
control. The blue fluorescence indicates the nuclei stain with DAPI. (For interpretation of the references to color in this figure
legend, the reader is referred to the web version of this article.)
Prospects of gene therapy for inherited pulmonary diseases 47lungs that are under inflammatory conditions. It is likely
that a viral vector, instead of nonviral vector, will have a
better chance to be successful in clinical applications since
current nonviral vectors cannot confer long term thera-
peutic gene expression. Viruses are professional gene car-
riers and have evolved molecular mechanisms to enter a
cell and inject the DNA into cell nuclei efficiently. As shown
in Fig. 1, recent studies using single-virus tracking tech-
niques in live cells revealed many of the molecular mech-
anisms that different viruses use to gain entry into
mammalian cells.141 All the advanced viral vectors do not
have viral genes, but they maintain the ability to send their
genomes efficiently into the nuclear compartment of target
cells. In addition to the high efficiency in delivering genes
to cells, the viral vector DNA is stable in transduced cells as
long as host innate immune responses can be minimized. All
these features of viral vectors are unmatched by nonviral
vectors. Currently, the most hopeful viral vector for lung
gene therapy, in our opinion, is the HD-Ad vector because
its high efficiency in gene delivery has been demonstrated
for transgene expression in mice, rabbits and pigs.47e50,84
Second, safe and efficient delivery methods are critical
for a clinical success. If the delivery method is too invasive
or too stressful, it will likely enhance the host innate im-
mune responses which will reduce the therapeutic efficacy.
If the method is not efficient, the therapeutic benefits willinternalization and transport through the actin matrix, vesicles th
microtubules towards the microtubule organizing center (MTOC).
caveosomes or the endoplasmic reticulum, prior to the release of t
dynein or dynactin along microtubules. From the MTOC, capsids ca
nucleus (5). Some viruses release their genetic material into the cy
The key shows how the different components have been labeled p
cytosis of Simian virus 40 (SV40). The arrowheads indicate SV40-con
SV40 particles are shown in red and the fluorescent protein-labeled
bar represents 3 mm. Inset panel reproduced with permission from t
the Advancement of Science. (For interpretation of the references
version of this article.)be reduced. Over the past decade, our group has been
developing safe and efficient methods for vector delivery to
airways of large animals. Using the AeroProbe catheter
and the LABneb control system designed by Trudell Med-
ical International (London Ontario, Canada), we have
worked out conditions for efficient gene delivery to rabbit
airways.49 In these experiments the HD-Ad vector was
formulated with 0.01% or 0.1% LPC in PBS and aerosolized to
the rabbit airways through the AeroProbe catheter fitted
into an endotracheal tube. More recently, we modified the
method for efficient gene delivery to pig lungs.50 Since we
use pigs about 30 kg in weight, we insert the AeroProbe
catheter into a bronchoscope and aerosolize the HD-Ad
vectors formulated with 0.01% LPC in PBS into pig lungs.
As shown in Fig. 2, extensive human CFTR expression was
observed in pig lungs one week post vector delivery. This
method should be easily adapted for clinical studies since
most instruments, such as the bronchoscope and ventilation
machine as well as drugs for anesthesia are the same as
used in humans.
Third, since lung is an immune sensitive organ, it is
important to avoid the host immune responses. Even by
selecting the best vector and most safe and effective de-
livery method, we will still face the problem of the host
immune responses to viral vectors. Strategies to overcome
the host immune responses are discussed early in theat contain virus are transported by dynein or dynactin along
This might include trafficking of viruses through endosomes,
he virus into the cytoplasm. Capsids can also be transported by
n be transported by kinesin towards the replication site of the
tosol whereas others transport their genomes into the nucleus.
reviously. The inset panel shows the caveolin-mediated endo-
taining caveolae co-localized with actin tails. The dye-labeled
caveolin and actin are in purple and green, respectively. Scale
he article by Pelkmans et al142 (2002) American Association for
to color in this figure legend, the reader is referred to the web
48 E. Xia et al.article. The most practical approaches to minimize the host
immune responses are to reduce the vector dose as much as
possible and to use transient immunosuppression to reduce
the host immune responses.
Another critical consideration for improving lung gene
therapy is to examine gene therapy vectors in appropriate
preclinical animal models for the targeting disease. For
gene therapy targeting CF lung disease, CF mouse models
are not adequate enough for assessing the efficacy of gene
therapy vectors and delivery methods, because of the
major differences in lung biology between mice and
humans as mentioned early. Recently, two excellent animal
models (pig and ferret) for CF lung disease have been
created by scientists at the University of Iowa.131,132 Unlike
CF mice, knocking out the CFTR gene in pigs and ferrets
results in typical CF lung symptoms, including mucus plug-
ging and spontaneous lung infection. These animal models
will be very useful for testing gene therapy vectors and
delivery methods for treating CF.
Finally, sustained therapeutic gene expression is
required for a clinical success in lung gene therapy. The
most important way to maintain therapeutic gene expres-
sion is to protect the transduced cells from attack by host
immune cells. This point has been discussed already.
Although viral vectors are stable in lung cells, lung
epithelial cell turnover does occur naturally, which will
reduce the therapeutic gene expression. There are two
strategies that can be considered to overcome this prob-
lem. One strategy is to re-administer viral vectors once a
year. This requires transient immunosuppression to avoid
host immune responses to vector readministration. In mice,
this has been demonstrated.84 The second strategy is to
integrate the therapeutic gene into progenitor cells of
airway epithelium. This is a new, hot area of research and it
will push gene therapy into a new stage for clinical
applications.Summary
Despite the early unsuccessful clinical trials of CF lung gene
therapy, later decades of research has identified major
challenges and made progress in overcoming these chal-
lenges. Analyzing the factors fundamental to the success in
clinical studies of LCA2 gene therapy, we can learn a lot to
improve lung gene therapy development. To address these
challenges to lung gene therapy, we need to demonstrate
that the host immune responses to viral vectors can be
controlled effectively and sustained therapeutic gene
expression can be maintained. The whole gene therapy
field is still in its infancy. Even for eye gene therapy, there
are still a lot of challenges, such as, efficient delivery of
large genes to photoreceptor cells. With the molecular
techniques under constant evolution, more and more suc-
cessful gene therapy cases will emerge. It is matter of time
that gene therapy will be a main approach to treating ge-
netic diseases.Conflict of interest
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